Research Leader - Pharmacology

Req ID:  138156

Saffron Walden, GB, CB10 1XL US Harlow, GB, CM19 5TR

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

Charles River are looking for a dynamic and influential in vivo/in vitro Pharmacologist.   The role is primarily based at our Harlow or Chesterford Research Park site, although you will be expected to interact with teams distributed across other Charles River sites (UK, Europe and USA), and with a diverse range of clients across the world.
In this role you will sit at the interface between the in vitro drug discovery teams, Clients and the in vivo pharmacology teams.   You will be a key member of our multidisciplinary drug discovery team, providing strong scientific leadership to multiple projects and project teams, ensuring work is completed to a high standard.  The successful candidate will work closely with our Clients and Business Development team with regards to securing new business through establishing client needs and providing guidance as to how to achieve project goals.  You will also suggest and design new in vivo studies, as well as interpret the outcome of completed pharmacological studies within the drug discovery cascade.  


Main tasks & responsibilities: 
•    Work with clients, Business Development specialists and Client Services to understand the needs of potential clients and design (and price) studies that meet their needs
•    Oversee in vivo FFS studies within Charles River to cover aspects such as resourcing and scheduling of studies to ensure timely delivery of data
•    Provide scientific and project leadership to drive our Client drug discovery programs 
•    Ensure any new models and variants on existing models are validated to the clients' expectations prior to studies being run for clients
•    To maintain a comprehensive understanding of relevant scientific literature and its applicability to ongoing projects
•    To be able to work independently and as part of a team, to solve complex problems 
•    To mentor and coach other scientists in achieving their potential and advancing their careers 
•    Leading by example delivering CRL's core values; Care, lead, own and collaborate
•    To regularly interact with existing clients to ensure work is being performed to an acceptable standard, and to rationalize, plan and perform requests for additional project work as appropriate.


Profile and Requirements

•    Experience of the drug development process and be able to design a screening cascade
•    A track record of working on drug discovery programmes, preferably to development candidate selection
•    A broad understanding of the in vivo PD and disease model landscape  
•    The ability to design and interpret in vivo model data, and to put data into context with PK 
•    A track record in leading and motivating projects and teams in a drug discovery setting 
•    A dynamic and flexible approach towards achieving client-based objectives and meeting challenging deadlines
•    The ability to communicate confidently and effectively with clients and other Charles River sites via videoconferences, presentations and written reports.
•    Experience in the Respiratory therapeutic area would be advantageous (inhaled and oral delivery route and limitations of PD models for respiratory disease)


In return, Charles River offers a competitive salary and benefits package, with flexible working options and further opportunity for more progression and development. 

About Discovery
Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 350 patents and 80 preclinical drug candidates delivered to our sponsors in the past 17 years. Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased to $2.62 billion.


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.